drugset / Trial / NCT00225914

Study of Paxil Use in Menopausal Women

NCT00225914

RandomizedParallel-groupDouble-blindTreatment

Summary

To evaluate the efficacy, safety, and tolerability of Paroxetine treatment in perimenopausal and postmenopausal women who present with menopause-related symptoms after discontinuing hormone therapy (HT), in the presence or absence of concomitant symptoms of depression or anxiety.

Timeline

Start
2004-09
Primary completion
Completion
2006-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Paroxetine Small molecule 12.5 mg
Subject Paroxetine Small molecule 25 mg

Indications